All Photos(1)

Documents

Y0000750

Dorzolamide for system suitability

Name: Dorzolamide for system suitability
Brand: SIAL

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

Dorzolamide hydrochloride

Sign Into View Organizational & Contract Pricing

All Photos(1)

About This Item

Empirical Formula (Hill Notation):

C₁₀H₁₆N₂O₄S₃ · HCl

CAS Number:

130693-82-2

Molecular Weight:

360.90

Beilstein:

5896026

MDL number:

MFCD00884659

UNSPSC Code:

41116107

PubChem Substance ID:

329831128

NACRES:

NA.24

grade

pharmaceutical primary standard

API family

dorzolamide

manufacturer/tradename

EDQM

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

Cl.CCN[C@H]1C[C@H](C)S(=O)(=O)c2sc(cc12)S(N)(=O)=O

InChI

1S/C10H16N2O4S3.ClH/c1-3-12-8-4-6(2)18(13,14)10-7(8)5-9(17-10)19(11,15)16;/h5-6,8,12H,3-4H2,1-2H3,(H2,11,15,16);1H/t6-,8-;/m0./s1

InChI key

OSRUSFPMRGDLAG-QMGYSKNISA-N

Gene Information

human ... CA2(760)

Looking for similar products? Visit Product Comparison Guide

Related Categories

Analytical Reference Standards

Pharmacopeia & Metrological Institute Standards

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Dorzolamide for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

related product

Product No.

Description

Pricing

1225306

BP1069

Dorzolamide hydrochloride, British Pharmacopoeia (BP) Reference Standard

PHR1925

Dorzolamide hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material

BP1071

Dorzolamide impurity D, British Pharmacopoeia (BP) Reference Standard

BP1070

Dorzolamide impurity B, British Pharmacopoeia (BP) Reference Standard

Pictograms

GHS08,GHS07

Signal Word

Warning

Hazard Statements

H302,H373

Precautionary Statements

P260 - P264 - P270 - P301 + P312 - P314 - P501

Hazard Classifications

Acute Tox. 4 Oral - STOT RE 2

Target Organs

Central nervous system,Gastrointestinal tract,Bone,Blood,Bladder

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Topical dorzolamide for treatment of cystoid macular edema in patients with choroideremia.

Mohamed A Genead et al.

Retina (Philadelphia, Pa.), 32(4), 826-833 (2011-09-03)

: To determine the value of a topical carbonic anhydrase inhibitor on the macular thickness and function in choroideremia patients with cystoid macular edema. : Two choroideremia patients with cystoid macular edema, observed by spectral-domain optical coherence tomography, were treated

The effects of a fixed combination of 0.5% timolol and 1% dorzolamide on optic nerve head blood circulation.

Ikuyo Ohguro et al.

Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics, 28(4), 392-396 (2012-04-07)

The purpose of the present study is to evaluate the effects of a fixed combination of 0.5% timolol maleate (TM) and 1% dorzolamide hydrochloride (DZ) (FCTD(1%)) on optic nerve head (ONH) blood circulation. A drop of 0.5% TM, 1% DZ

Diurnal and nocturnal variations in aqueous humor dynamics of patients with ocular hypertension undergoing medical therapy.

Vikas Gulati et al.

Archives of ophthalmology (Chicago, Ill. : 1960), 130(6), 677-684 (2012-02-15)

To evaluate the interaction of intraocular pressure(IOP)–lowering medications with physiologic day and night changes in aqueous humor dynamics in participants with ocular hypertension. Thirty participants were enrolled in thisdouble-masked, randomized, crossover study. Each participant underwent aqueous humor dynamics measurements at

Therapeutic effect of prolonged treatment with topical dorzolamide for cystoid macular oedema in patients with retinitis pigmentosa.

Yasuhiro Ikeda et al.

The British journal of ophthalmology, 97(9), 1187-1191 (2013-06-21)

To evaluate the therapeutic effect of continuous treatment with topical dorzolamide (a carbonic anhydrase inhibitor) for cystoid macular oedema (CME) associated with retinitis pigmentosa (RP). 18 eyes in 10 patients with CME secondary to RP were included. Baseline visual acuity

Regulation of retinal proteome by topical antiglaucomatous eye drops in an inherited glaucoma rat model.

Maurice Schallenberg et al.

PloS one, 7(7), e33593-e33593 (2012-07-14)

Examination of the response of the retinal proteome to elevated intraocular pressure (IOP) and to the pharmacological normalization of IOP is crucial, in order to develop drugs with neuroptorective potential. We used a hereditary rat model of ocular hypertension to

View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service